Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen
- PMID: 7966200
- DOI: 10.1099/00222615-41-5-295
Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen
Abstract
Early reports of Candida krusei in man describe the organism as a transient, infrequent isolate of minor clinical significance inhabiting the mucosal surfaces. More recently it has emerged as a notable pathogen with a spectrum of clinical manifestations such as fungaemia, endophthalmitis, arthritis and endocarditis, most of which usually occur in compromised patient groups in a nosocomial setting. The advent of human immunodeficiency virus infection and the widespread use of the newer triazole fluconazole to suppress fungal infections in these patients have contributed to a significant increase in C. krusei infection, particularly because of the high incidence of resistance of the yeast to this drug. Experimental studies have generally shown C. krusei to be less virulent than C. albicans in terms of its adherence to both epithelial and prosthetic surfaces, proteolytic potential and production of phospholipases. Furthermore, it would seem that C. krusei is significantly different from other medically important Candida spp. in its structural and metabolic features, and exhibits different behaviour patterns towards host defences, adding credence to the belief that it should be re-assigned taxonomically. An increased awareness of the pathogenic potential of this yeast coupled with the newer molecular biological approaches to its study may facilitate the continued exploration of the epidemiology and pathogenesis of C. krusei infections.
Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility.Clin Infect Dis. 1992 Mar;14(3):756-66. doi: 10.1093/clinids/14.3.756. Clin Infect Dis. 1992. PMID: 1345554 Review.
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
-
[Candida krusei (Castellani) Berkhout--a potential pathogen with growing importance].Epidemiol Mikrobiol Imunol. 1998 Dec;47(4):137-40. Epidemiol Mikrobiol Imunol. 1998. PMID: 9919813 Czech.
-
Fungal endophthalmitis.Ophthalmology. 1998 Jul;105(7):1129-30. doi: 10.1016/S0161-6420(98)97008-7. Ophthalmology. 1998. PMID: 9663211 No abstract available.
Cited by
-
Qualitative assessment of the removable denture microbiome.Germs. 2024 Mar 31;14(1):28-37. doi: 10.18683/germs.2024.1415. eCollection 2024 Mar. Germs. 2024. PMID: 39169976 Free PMC article.
-
In Vitro Antifungal Activity of Three Synthetic Peptides against Candida auris and Other Candida Species of Medical Importance.Antibiotics (Basel). 2023 Jul 26;12(8):1234. doi: 10.3390/antibiotics12081234. Antibiotics (Basel). 2023. PMID: 37627654 Free PMC article.
-
Biological Activities of the Fruit Essential Oil, Fruit, and Root Extracts of Ferula drudeana Korovin, the Putative Anatolian Ecotype of the Silphion Plant.Plants (Basel). 2023 Feb 13;12(4):830. doi: 10.3390/plants12040830. Plants (Basel). 2023. PMID: 36840178 Free PMC article.
-
Profuse diversity and acidogenicity of the candida-biome of deep carious lesions of Severe Early Childhood Caries (S-ECC).J Oral Microbiol. 2021 Aug 24;13(1):1964277. doi: 10.1080/20002297.2021.1964277. eCollection 2021. J Oral Microbiol. 2021. PMID: 34447489 Free PMC article.
-
[Study on growth characteristics of Candida auris under different conditions in vitro and its in vivo toxicity].Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jul 30;40(7):1049-1055. doi: 10.12122/j.issn.1673-4254.2020.07.21. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 32895165 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous